Voyager Therapeutics (NASDAQ:VYGR) Lifted to “Buy” at StockNews.com

StockNews.com upgraded shares of Voyager Therapeutics (NASDAQ:VYGR) from a hold rating to a buy rating in a research report sent to investors on Friday.

Several other equities research analysts have also recently issued reports on the company. Wedbush reduced their target price on Voyager Therapeutics from $8.00 to $7.00 and set a neutral rating on the stock in a report on Wednesday, August 7th. HC Wainwright reaffirmed a buy rating and issued a $30.00 price objective on shares of Voyager Therapeutics in a research note on Tuesday, August 20th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, Voyager Therapeutics currently has a consensus rating of Moderate Buy and a consensus target price of $17.83.

Voyager Therapeutics Price Performance

VYGR stock opened at $7.18 on Friday. The company has a market capitalization of $390.55 million, a price-to-earnings ratio of -143.60 and a beta of 0.91. Voyager Therapeutics has a 1-year low of $5.71 and a 1-year high of $11.72. The business has a 50 day simple moving average of $6.52 and a two-hundred day simple moving average of $7.76.

Voyager Therapeutics (NASDAQ:VYGR) last posted its earnings results on Tuesday, August 6th. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.38) by $0.20. The company had revenue of $29.58 million during the quarter, compared to analysts’ expectations of $11.52 million. Voyager Therapeutics had a net margin of 6.28% and a return on equity of 3.31%. During the same period last year, the company posted ($0.51) earnings per share. Sell-side analysts anticipate that Voyager Therapeutics will post -1.44 EPS for the current fiscal year.

Insider Buying and Selling at Voyager Therapeutics

In other news, insider Sandell Jacquelyn Fahey sold 5,999 shares of Voyager Therapeutics stock in a transaction that occurred on Wednesday, October 2nd. The stock was sold at an average price of $5.82, for a total value of $34,914.18. Following the completion of the transaction, the insider now owns 86,001 shares in the company, valued at approximately $500,525.82. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 4.53% of the company’s stock.

Institutional Investors Weigh In On Voyager Therapeutics

Institutional investors have recently made changes to their positions in the company. Ameritas Investment Partners Inc. raised its position in Voyager Therapeutics by 49.6% in the 1st quarter. Ameritas Investment Partners Inc. now owns 3,923 shares of the company’s stock worth $37,000 after purchasing an additional 1,300 shares during the period. Victory Capital Management Inc. grew its stake in shares of Voyager Therapeutics by 14.5% during the second quarter. Victory Capital Management Inc. now owns 12,892 shares of the company’s stock valued at $102,000 after buying an additional 1,630 shares during the last quarter. SummerHaven Investment Management LLC raised its holdings in shares of Voyager Therapeutics by 2.5% in the second quarter. SummerHaven Investment Management LLC now owns 77,293 shares of the company’s stock worth $611,000 after buying an additional 1,921 shares during the period. Allspring Global Investments Holdings LLC lifted its stake in shares of Voyager Therapeutics by 2.1% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 99,306 shares of the company’s stock worth $925,000 after acquiring an additional 2,030 shares during the last quarter. Finally, Federated Hermes Inc. boosted its holdings in Voyager Therapeutics by 0.5% during the 2nd quarter. Federated Hermes Inc. now owns 554,214 shares of the company’s stock valued at $4,384,000 after acquiring an additional 2,638 shares during the period. Institutional investors own 48.03% of the company’s stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.